These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15539141)

  • 1. Molecular biomarkers in drug development.
    Lewin DA; Weiner MP
    Drug Discov Today; 2004 Nov; 9(22):976-83. PubMed ID: 15539141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative proteomics for drug toxicity.
    Gao Y; Holland RD; Yu LR
    Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.
    Gundert-Remy U; Dahl SG; Boobis A; Kremers P; Kopp-Schneider A; Oberemm A; Renwick A; Pelkonen O
    Toxicol Lett; 2005 Apr; 156(2):227-40. PubMed ID: 15737486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.
    Colburn WA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1419-27. PubMed ID: 11185662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
    Severino ME; Dubose RF; Patterson SD
    IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics and proteomics in process development: opportunities and challenges.
    Gupta P; Lee KH
    Trends Biotechnol; 2007 Jul; 25(7):324-30. PubMed ID: 17475353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling approaches for identifying novel biomarkers.
    Bailey WJ; Ulrich R
    Expert Opin Drug Saf; 2004 Mar; 3(2):137-51. PubMed ID: 15006720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
    Calvo KR; Liotta LA; Petricoin EF
    Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P; Sasaki J
    Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
    Ferrer-Alcón M; Arteta D; Guerrero MJ; Fernandez-Orth D; Simón L; Martinez A
    Toxicol Lett; 2009 Apr; 186(1):45-51. PubMed ID: 19022361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical biodescriptors of proteomics maps: background and applications.
    Basak SC; Gute BD
    Curr Opin Drug Discov Devel; 2008 May; 11(3):320-6. PubMed ID: 18428085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B; Ball G; Rees R
    Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.